Akkermansia muciniphila is a naturally occurring gut bacterium that plays a key role in maintaining the intestinal mucus lining, and it has become one of the most studied next-generation probiotics in recent years. Research suggests that higher levels of this microbe are associated with improved metabolic markers, including better blood sugar regulation, reduced inflammation, and healthier body weight, while lower levels have been observed in individuals with obesity and type 2 diabetes. Studies indicate that the pasteurized (heat-treated) form may actually be more effective than the live bacterium, with promising clinical trials showing improvements in insulin sensitivity and cholesterol levels in overweight adults. Though research is still evolving, Akkermansia muciniphila represents an exciting frontier in understanding how specific gut microbes influence broader metabolic and immune health.
Compare this supplementResearch suggests that Akkermansia muciniphila, a mucus-dwelling gut bacterium, plays a meaningful role in supporting...
View studies →Research suggests that Akkermansia muciniphila may play a meaningful role in weight management and metabolic health, ...
View studies →Research suggests that Akkermansia muciniphila may play a meaningful role in reducing intestinal and systemic inflamm...
View studies →Research suggests that Akkermansia muciniphila plays a biologically active role in gut metabolism, particularly throu...
View studies →The studies provided do not contain research relevant to Akkermansia muciniphila or blood sugar regulation. The avail...
View studies →These are commonly referenced dosage ranges for this supplement. They are not medical recommendations. Always consult a healthcare provider before supplementing.
| Form | Dose range | Frequency | Studied for | Source |
|---|---|---|---|---|
| Capsule | 99,999,999.99 CFU | Daily | anti-inflammatory, insulin sensitivity, obesity | Range spanning low and high dose arms in Depommier et al. 2019; pasteurized form shown superior to live |
| Capsule | 99,999,999.99 CFU | Daily | cardiometabolic risk reduction, blood sugar regulation | Pasteurized A. muciniphila at 10^9 CFU daily for 3 months improved insulin sensitivity markers in Depommier et al. 2019 |
| Capsule | 99,999,999.99 CFU | Daily | gut health, metabolic support, weight management | Used in Plovier et al. 2017 and Depommier et al. 2019 RCTs with pasteurized A. muciniphila at 10^9 CFU |
| Capsule | 99,999,999.99 CFU | Daily | gut health, metabolic syndrome, blood sugar regulation | Higher dose arm evaluated in Depommier et al. 2019 Phase I trial (NCT02637115) |